X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs ASTRAZENECA PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD ASTRAZENECA PHARMA MERCK LTD/
ASTRAZENECA PHARMA
 
P/E (TTM) x 52.6 157.6 33.4% View Chart
P/BV x 7.9 24.5 32.4% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 MERCK LTD   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
ASTRAZENECA PHARMA
Mar-14
MERCK LTD/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0601,285 82.5%   
Low Rs623634 98.3%   
Sales per share (Unadj.) Rs632.4189.6 333.6%  
Earnings per share (Unadj.) Rs45.7-0.2 -22,454.3%  
Cash flow per share (Unadj.) Rs62.33.8 1,620.9%  
Dividends per share (Unadj.) Rs11.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs388.868.6 566.5%  
Shares outstanding (eoy) m16.6025.00 66.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.1 26.3%   
Avg P/E ratio x18.4-4,712.7 -0.4%  
P/CF ratio (eoy) x13.5249.6 5.4%  
Price / Book Value ratio x2.214.0 15.5%  
Dividend payout %24.10-   
Avg Mkt Cap Rs m13,96923,988 58.2%   
No. of employees `0001.61.6 101.5%   
Total wages/salary Rs m1,4871,605 92.7%   
Avg. sales/employee Rs Th6,631.93,040.2 218.1%   
Avg. wages/employee Rs Th939.21,029.2 91.2%   
Avg. net profit/employee Rs Th479.4-3.3 -14,683.6%   
INCOME DATA
Net Sales Rs m10,4984,740 221.5%  
Other income Rs m24292 263.2%   
Total revenues Rs m10,7414,832 222.3%   
Gross profit Rs m1,135-130 -874.7%  
Depreciation Rs m276101 272.2%   
Interest Rs m00-   
Profit before tax Rs m1,102-139 -793.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m3435 6,744.6%   
Profit after tax Rs m759-5 -14,909.6%  
Gross profit margin %10.8-2.7 -394.9%  
Effective tax rate %31.1-3.7 -850.0%   
Net profit margin %7.2-0.1 -6,731.3%  
BALANCE SHEET DATA
Current assets Rs m6,4102,726 235.1%   
Current liabilities Rs m8,8282,435 362.6%   
Net working cap to sales %-23.06.1 -374.8%  
Current ratio x0.71.1 64.8%  
Inventory Days Days5874 78.2%  
Debtors Days Days3841 94.2%  
Net fixed assets Rs m1,4061,035 135.8%   
Share capital Rs m16650 332.0%   
"Free" reserves Rs m6,286942 667.0%   
Net worth Rs m6,4551,716 376.1%   
Long term debt Rs m00-   
Total assets Rs m8,8284,156 212.4%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.1 104.3%   
Return on assets %8.6-0.1 -7,018.8%  
Return on equity %11.8-0.3 -3,963.8%  
Return on capital %17.10-  
Exports to sales %8.35.7 145.3%   
Imports to sales %21.06.5 325.6%   
Exports (fob) Rs m869270 321.8%   
Imports (cif) Rs m2,209306 721.3%   
Fx inflow Rs m959375 256.0%   
Fx outflow Rs m2,612470 555.6%   
Net fx Rs m-1,653-96 1,730.2%   
CASH FLOW
From Operations Rs m1,070-8 -13,214.8%  
From Investments Rs m-750-146 514.6%  
From Financial Activity Rs m-150862 -17.4%  
Net Cashflow Rs m171709 24.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 0.3 6,066.7%  
FIIs % 1.0 15.7 6.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 9.1 319.8%  
Shareholders   28,591 12,856 222.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   TORRENT PHARMA  ALEMBIC PHARMA  AJANTA PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - PANACEA BIOTECH COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS